公开(公告)号：US20240277791A1

公开(公告)日：2024-08-22

申请号：US18568574

申请日：2022-06-10

Applicant: Integrated Pharma Services, LLC

Inventor： Mina Izadjoo ,  Hosan Kim ,  Salman Izadjoo

IPC: A61K35/76 ,  A61K9/00 ,  A61K9/06 ,  A61K38/16 ,  A61K38/47 ,  A61K47/34 ,  A61K47/38 ,  A61P17/10 ,  A61P31/04 ,  C07K14/005 ,  C12N7/00 ,  C12N9/36

CPC classification number: A61K35/76 ,  A61K9/0014 ,  A61K9/06 ,  A61K38/162 ,  A61K38/47 ,  A61K47/34 ,  A61K47/38 ,  A61P17/10 ,  A61P31/04 ,  C07K14/005 ,  C12N7/00 ,  C12N9/2462 ,  C12Y302/01017 ,  C12N2795/00021 ,  C12N2795/00022 ,  C12N2795/00032

Abstract: Recombinantly-modified Cutibacterium acnes-specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.

公开(公告)号：US20240150725A1

公开(公告)日：2024-05-09

申请号：US18278775

申请日：2021-06-15

Applicant: CJ CheilJedang Corporation

Inventor： Jong Soo JEON ,  Ji Eun KIM ,  Jun Ok MOON ,  Jong Pyo CHAE ,  Yu Jin KIM ,  Seung Eun LEE

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2795/00021 ,  C12N2795/00031 ,  C12N2795/00032 ,  C12N2795/00051

Abstract: The present disclosure relates to a novel bacteriophage having ability to specifically kill Clostridium perfringens and an antibacterial composition comprising the same. The novel bacteriophage CJ_CP_20-25 has the effect of specifically killing Clostridium perfringens, exhibits excellent acid resistance and heat resistance, and can thus be widely used in antibiotics, feed additives, drinking water additives, feed, drinking water, disinfectants, or cleaning agents for the prevention or treatment of infectious diseases caused by Clostridium perfringens.

公开(公告)号：US20230398162A1

公开(公告)日：2023-12-14

申请号：US18034746

申请日：2021-10-19

Applicant: Oxana Karpf

Inventor： Oxana Karpf

IPC: A61K35/76 ,  C12N7/00

CPC classification number: A61K35/76 ,  C12N7/00 ,  C12N2795/00032

Abstract: The invention relates to a method for reducing the population of at least one intestinal and/or gastrointestinal species of bacteria, the method comprising the following steps:



a) providing a biological sample containing bacteria of at least one intestinal and/or gastrointestinal species of bacteria, the intestinal and/or gastrointestinal species of bacteria directly or indirectly influencing a psychological, neurodegenerative and/or neurological illness and/or disorder of a host organism; and
b) providing bacteriophages of at least one species of bacteriophages that are specific to the intestinal and/or gastrointestinal species of bacteria and that comprise at least one nucleic acid functionally associated with a promotor and/or a regulatory element; and
c) contacting and incubating the biological sample with the bacteriophages, the incubation continuing until the population of the intestinal and/or gastrointestinal species of bacteria has been reduced by at least 70%.

公开(公告)号：US11692229B2

公开(公告)日：2023-07-04

申请号：US17033034

申请日：2020-09-25

Applicant: The Regents of the University of California

Inventor： Huiying Li ,  Shuta Tomida ,  Robert L. Modlin ,  Jeffery F. Miller ,  Sorel T. Fitz-Gibbon

IPC: C12Q1/689 ,  C12Q1/6883 ,  A61K39/05 ,  A61K35/741 ,  A61K35/76 ,  A61K39/02 ,  C12N7/00 ,  C12Q1/70

CPC classification number: C12Q1/689 ,  A61K35/741 ,  A61K35/76 ,  A61K39/0208 ,  A61K39/05 ,  C12N7/00 ,  C12Q1/6883 ,  C12Q1/701 ,  C12N2795/00032 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

公开(公告)号：US11684587B2

公开(公告)日：2023-06-27

申请号：US17813871

申请日：2022-07-20

Applicant: PHAGELUX (CANADA) INC.

Inventor： Nancy Tawil ,  Ramaz Katsarava ,  David Tugushi ,  Vakhtang Beridze

IPC: A61K9/70 ,  A61K33/38 ,  A61K35/76 ,  A61K47/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/635 ,  A61K31/785 ,  A61K47/34 ,  A61L26/00 ,  A61P17/00 ,  C12N7/00 ,  A61K45/06

CPC classification number: A61K9/7069 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/143 ,  A61K9/7007 ,  A61K31/635 ,  A61K31/785 ,  A61K33/38 ,  A61K35/76 ,  A61K47/02 ,  A61K47/34 ,  A61L26/0019 ,  A61L26/0066 ,  A61P17/00 ,  C12N7/00 ,  A61K45/06 ,  A61L2300/104 ,  C12N2795/00021 ,  C12N2795/00032 ,  A61L26/0019 ,  C08L75/04

Abstract: A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

公开(公告)号：US20180105792A1

公开(公告)日：2018-04-19

申请号：US15831591

申请日：2017-12-05

Applicant: BOBBAN SUBHADRA

Inventor： BOBBAN SUBHADRA

IPC: C12N1/20 ,  C12M1/12 ,  A61K9/00 ,  A61K35/74 ,  C12N7/00 ,  C12N1/04 ,  C12M1/34 ,  C12M1/00 ,  C12M3/00 ,  A61K35/00

CPC classification number: C12N1/20 ,  A61K9/0031 ,  A61K9/0053 ,  A61K35/74 ,  A61K2035/11 ,  C12M23/02 ,  C12M23/06 ,  C12M23/20 ,  C12M23/42 ,  C12M25/10 ,  C12M41/12 ,  C12M41/14 ,  C12M41/34 ,  C12N1/04 ,  C12N7/00 ,  C12N2795/00021 ,  C12N2795/00032 ,  C12N2795/00051 ,  C12R1/01 ,  C12R1/145 ,  C12R1/19 ,  C12R1/46 ,  G01N33/558 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/475

Abstract: One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

公开(公告)号：US20180030403A1

公开(公告)日：2018-02-01

申请号：US15221927

申请日：2016-07-28

Applicant: Bobban Subhadra

Inventor： Bobban Subhadra

IPC: C12N1/20 ,  C12M1/00 ,  C12M1/34 ,  A61K9/00 ,  C12N1/04 ,  C12N7/00 ,  A61K35/74 ,  C12M1/12 ,  C12M3/00

CPC classification number: C12N1/20 ,  A61K9/0031 ,  A61K9/0053 ,  A61K35/74 ,  A61K2035/11 ,  C12M23/02 ,  C12M23/06 ,  C12M23/20 ,  C12M23/42 ,  C12M25/10 ,  C12M41/12 ,  C12M41/14 ,  C12M41/34 ,  C12N1/04 ,  C12N7/00 ,  C12N2795/00021 ,  C12N2795/00032 ,  C12N2795/00051 ,  C12R1/01 ,  C12R1/145 ,  C12R1/19 ,  C12R1/46 ,  G01N33/558 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/475

Abstract: One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

公开(公告)号：US09795642B2

公开(公告)日：2017-10-24

申请号：US14779159

申请日：2014-03-25

Applicant: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  J. CRAIG VENTER INSTITUTE, INC.

Inventor： Roy H. Stevens ,  Hongming Zhang ,  Derrick E. Fouts ,  Jessica DePew

IPC: A61K35/76 ,  A01N63/00 ,  C12N7/00 ,  A61K9/00 ,  A61L26/00

CPC classification number: A61K35/76 ,  A01N63/00 ,  A61K9/0014 ,  A61L26/0057 ,  A61L26/0066 ,  A61L2300/404 ,  C12N7/00 ,  C12N2795/00021 ,  C12N2795/00032 ,  C12N2795/10121 ,  C12N2795/10122 ,  C12N2795/10321 ,  C12N2795/10322

Abstract: Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.

公开(公告)号：US09789140B2

公开(公告)日：2017-10-17

申请号：US15260879

申请日：2016-09-09

Applicant: Crestovo LLC

Inventor： Thomas Julius Borody

IPC: A61K39/08 ,  A61K39/00 ,  A61K39/38 ,  A61K39/116 ,  A61K39/09 ,  A01N63/00 ,  A01N65/00 ,  A61K35/742 ,  A61K35/74 ,  A61K38/48 ,  A61K35/741 ,  A61K35/744 ,  A61K35/747 ,  A61K36/062 ,  A61K45/06 ,  A61K38/14 ,  A61K31/341 ,  A61K31/41 ,  A61K31/495 ,  A61K31/7034 ,  A23L2/52 ,  A61K35/745 ,  A61K35/38 ,  A61K35/24 ,  A61K9/00 ,  A23C9/123 ,  A61K9/48 ,  A23C9/13 ,  A23L33/135 ,  A23C9/127 ,  A61K9/19 ,  A61K35/37 ,  A61K31/545 ,  A61K35/76 ,  A61K31/43 ,  A61K38/00 ,  A61K31/7048 ,  A61K9/50 ,  A61K39/39 ,  A61K51/12 ,  A61K35/00

CPC classification number: A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US09701964B2

公开(公告)日：2017-07-11

申请号：US15160405

申请日：2016-05-20

Applicant: SNIPR TECHNOLOGIES LIMITED

Inventor： Jasper Clube ,  Morten Sommer ,  Christian Grøndahl ,  Eric Van Der Helm ,  Ruben Vazquez-Uribe

IPC: C12N15/13 ,  C12N15/113 ,  C12N15/74 ,  C12N15/70 ,  A61K31/711 ,  A61K45/06 ,  A01N63/00 ,  A61K31/7105

CPC classification number: A01N63/00 ,  A61K31/7105 ,  A61K31/711 ,  A61K45/06 ,  A61K48/005 ,  A61K2300/00 ,  C12N1/20 ,  C12N7/00 ,  C12N9/16 ,  C12N15/102 ,  C12N15/113 ,  C12N15/70 ,  C12N15/746 ,  C12N2310/20 ,  C12N2320/31 ,  C12N2795/00032 ,  Y02A50/473 ,  Y02A50/481

Abstract: The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.